Algernon Pharmaceutical CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has announced positive information showing the company has met its Phase 2 proof of concept study evaluating Ifenprodil in the treatment of idiopathic pulmonary fibrosis and chronic cough. Moreau telling Proactive the data has shown 65% of patients had stable or improved forced vital capacity over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%. Moreau says FVC is the amount of air that can be forcibly exhaled from one's lungs after taking the deepest breath possible. The Company plans to release the entire report in August and also plan to discuss the results at the International Colloquium on Lung and Airway Fibrosis in Iceland this October.
Algernon Pharmaceuticals study of Ifenprodil for Fibrosis and chronic cough reaches key stage
